Acquired and intrinsic resistance to colorectal cancer treatment

Romina Briffa, Simon Langdon, Godfrey Grech, David Harrison

Research output: Chapter in Book/Report/Conference proceedingChapter (peer-reviewed)peer-review


First line therapy for colorectal cancer (CRC) is usually fluoropyrimidine
monotherapy and oxaliplatin, or irinotecan based therapy. Additionally, targeted therapies such as bevacizumab, aflibercept, ramucirumab, regorafenib, cetuximab and panitumumab are indicated in combination with chemotherapy in metastatic CRC. Resistance of CRC to treatment is the principal rationale for treatment failure. Resistance can be intrinsic (primary resistance) or acquired (secondary resistance). Here, we discuss the classical model of resistance, which focuses primarily on mechanisms involving alterations in drug metabolism, increased drug efflux, secondary mutations in drug targets, inactivation of apoptotic pathways, p53 and DNA damage repair. Other resistance mechanisms, including the Warburg effect, cancer stem cells, intra-tumour heterogeneity, and pharmacoepigenomic mechanisms will also be discussed. We conclude the chapter with a systems medicine approach to predict response to treatment for the discovery and validation of predictive biomarkers that are urgently needed.
Original languageEnglish
Title of host publicationColorectal Cancer
Subtitle of host publicationDiagnosis, Screening and Management
EditorsJindong Chen
ISBN (Electronic)978-1-78923-101-4
ISBN (Print)978-1-78923-100-7
Publication statusPublished - 16 May 2018


Dive into the research topics of 'Acquired and intrinsic resistance to colorectal cancer treatment'. Together they form a unique fingerprint.

Cite this